reports
Catalyst Pharmaceuticals to Report Third Quarter 2025 Financial Result...
Catalyst Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 5, 2025 The Company will Host a Conference Call and Webcast on Thursday, November 6, 2025, at 8:30 AM ET CORAL GABLES, Fla., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its third quarter 2025 financial results after the market c...
Celcuity Provides Update on Status of the PIK3CA Mutated Cohort of Pha...
Celcuity Provides Update on Status of the PIK3CA Mutated Cohort of Phase 3 VIKTORIA-1 Trial and Releases Additional Data Analysis From Phase 1b Clinical Trial PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 clinical trial is fully enrolledAdditional analysis of data from a Phase 1b clinical trial that included all patients treated with gedatolisib combined with fulvestrant and palbociclib showed median progression-free survival (“PFS”) of 14.6 months in patients with HR+/HER2-/PIK3CA-mutated advanced breast cancer (“ABC”) MINNEAPOLIS, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasda...
Celcuity Presents Updated Data at the 2025 ESMO Congress from Phase 1 ...
Celcuity Presents Updated Data at the 2025 ESMO Congress from Phase 1 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration Resistant Prostate Cancer (“mCRPC”) Median radiographic progression free survival (“rPFS”) was 9.1 months and the six-month rPFS rate was 67% No patients discontinued study treatment due to a treatment-related adverse event (“TRAE”) MINNEAPOLIS, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced updated clinical resu...
Detailed Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Tr...
Detailed Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate Potential for Gedatolisib Regimens to be Practice Changing for Patients with HR+/HER2- Advanced Breast Cancer Clinical benefit of the gedatolisib regimens was consistent across patient subgroups Hyperglycemia was reported in only 9.2% of patients treated with gedatolisib + palbociclib + fulvestrant (“gedatolisib triplet”) and in 11.5% of patients treated with gedatolisib + fulvestrant (“gedatolisib doublet”)Study treatment discontinuation due to treatment related adverse eve...
Catalyst Pharmaceuticals Announces Presentations at Upcoming Scientifi...
Catalyst Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences CORAL GABLES, Fla., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing and commercializing novel medicines for people living with rare and difficult-to-treat diseases, today announced that data developed by or in conjunction with the company will be presented at several upcoming scientific conferences, details of which are listed below. "At Catalyst, everything begins with patients. ...
- Jonathan Moreland
TPVG TRIPLEPOINT VENTURE GROWTH BDC CORP
PSEC PROSPECT CAPITAL CORPORATION
NVCR NOVOCURE LTD.
MTDR MATADOR RESOURCES COMPANY
FCN FTI CONSULTING INC.
AROW ARROW FINANCIAL CORP.
MDU MDU RESOURCES GROUP INC
CULP CULP INC.
PBHC PATHFINDER BANCORP INC.
ESP ESPEY MANUFACTURING & ELECTRONICS CORP.
BSM BLACK STONE MINERALS LP
HAIN THE HAIN CELESTIAL GROUP
SMRT INC.
CELC SMARTSPACE SOFTWARE
MBIN CELCUITY
CCEL MERCHANTS BANCORP
BCDA CRYO-CELL INTERNATIONAL
DX BIOCARDIA
COO DYNEX CAPITAL INC.
AOUT THE COOPER COMPANIES INC.
ALXO AMERICAN OUTDOOR BRANDS
SMMT INC.
NAUT ALX ONCOLOGY HOLDINGS
ENOV SUMMIT THERAPEUTICS INC
MRVL NAUTILUS BIOTECHNOLOGY INC
UAMY ENOVIS CORPORATION
NCDL MARVEL BIOSCIENCES CORP
NEXT U S ANTIMONY CORP
SFD NUVEEN CHURCHILL DIRECT LENDING CORP
AFCG NEXTSOURCE MATERIALS INC.
SI SMITHFIELD FOODS INC.
JSPR AFC GAMMA
INC.
SHOULDER INNOVATIONS INC
AMPLITUDE HEALTHCARE ACQUISITION CORP
Catalyst Pharmaceuticals Announces $200 Million Share Repurchase Progr...
Catalyst Pharmaceuticals Announces $200 Million Share Repurchase Program CORAL GABLES, Fla., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing and commercializing novel medicines for people living with rare and difficult-to-treat diseases, today announced that its Board of Directors has authorized a new share repurchase program to repurchase up to $200 million of shares of Catalyst's outstanding common stock between October 1, 2025, and December 31, 202...
- Jonathan Moreland
Option Care Health to Announce Third Quarter 2025 Financial Results an...
Option Care Health to Announce Third Quarter 2025 Financial Results and Host Conference Call BANNOCKBURN, Ill., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Option Care Health Inc. (“Option Care Health”) (NASDAQ: OPCH), the nation’s largest independent provider of home and alternate site infusion services, today announced that the company will release results for its third quarter ended September 30, 2025 on Thursday, October 30, 2025 before the market opens. In conjunction, the management team will host a conference call to review the results at 8:30 a.m. E.T. on the same day. Conference Call Det...
Celcuity to Present Results from the Pivotal Phase 3 VIKTORIA-1 Trial ...
Celcuity to Present Results from the Pivotal Phase 3 VIKTORIA-1 Trial at the 2025 European Society for Medical Oncology (ESMO) Congress MINNEAPOLIS, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that a late breaking abstract reporting clinical data from the Phase 3 VIKTORIA-1 trial has been selected for an oral presentation at the upcoming European Society of Medical Oncology (ESMO) Congress, being held October 17-21, 2025. The presentation will provide detail...
- Jonathan Moreland
SNPS SYNOPSYS INC.
NMFC NEW MOUNTAIN FINANCE CORPORATION
NGL NGL ENERGY PARTNERS LP
MTDR MATADOR RESOURCES COMPANY
FRPT FRESHPET INC
BUSE FIRST BUSEY CORPORATION
ASA ASA
CELC CELCUITY
MBIN MERCHANTS BANCORP
AROC ARCHROCK INC.
CCEL CRYO-CELL INTERNATIONAL
GRX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
ALXO ALX ONCOLOGY HOLDINGS
DLHC DALEIGH HOLDINGS CORP
AMR ALPHA METALLURGICAL RESOURCES INC
OPEN OPENDOOR TECHNOLOGIES INC.
CTO CONSOLIDATED-TOMOKA LAND CO
PFBX PEOPLES FINANCIAL CORP. (MISSISSIPPI)
NEXT NEXT CAPITAL
RYAN RYAN SPECIALTY GROUP HLDGS INC
KMPH KEMPHARM INC
BUKS BUTLER NATIONAL CORP
OBLG OBLONG INC
VANI VIVANI MEDICAL INC
RH RESTORATION HARDWARE HOLDINGS INC
SMRT SMARTRENT INC
NBBK NB BANCORP INC.
NCDL NUVEEN CHURCHILL DIRECT LENDING CORP
BHRB BURKE HERBERT FINANCIAL SERVICES CORP
CAMP CAMP4 THERAPEUTICS CORPORATION
SI SHOULDER INNOVATIONS INC
MSTR MICROSTRATEGY INCORPORATED
- Jonathan Moreland
- Jonathan Moreland
- Jonathan Moreland
MTDR MATADOR RESOURCES COMPANY
ASA ASA
PBHC PATHFINDER BANCORP INC.
NEXT NEXTDECADE
CELC CELCUITY
FGBI FIRST GUARANTY BANCSHARES
GRX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
OPEN OPENDOOR TECHNOLOGIES INC.
PFBX PEOPLES FINANCIAL CORP. (MISSISSIPPI)
RYAN RYAN SPECIALTY GROUP HLDGS INC
KMPH KEMPHARM INC
NBBK NB BANCORP INC.
BHRB BURKE HERBERT FINANCIAL SERVICES CORP
CAMP CAMP4 THERAPEUTICS CORPORATION
SI SHOULDER INNOVATIONS INC
- Jonathan Moreland
CDNA CAREDX INC
AROW ARROW FINANCIAL CORP.
ESP ESPEY MANUFACTURING & ELECTRONICS CORP.
BSM BLACK STONE MINERALS LP
PLSE PULSE BIOSCIENCES
DLHC DALEIGH HOLDINGS CORP
CTO CONSOLIDATED-TOMOKA LAND CO
PFBX PEOPLES FINANCIAL CORP. (MISSISSIPPI)
HYMC HYCROFT MINING HOLDING CORPORATION
- Jonathan Moreland
SBH SALLY BEAUTY HOLDINGS INC.
PRGO PERRIGO CO. PLC
NVCR NOVOCURE LTD.
KURA KURA ONCOLOGY INC.
GLP GLOBAL PARTNERS LP
FRPT FRESHPET INC
FLDM FLUIDIGM
FCN FTI CONSULTING INC.
CPRX CATALYST PHARMACEUTICALS
CE CELANESE CORPORATION
CDNA CAREDX INC
ASA ASA
AROW ARROW FINANCIAL CORP.
MDU MDU RESOURCES GROUP INC
ADC AGREE REALTY CORPORATION
CECE CECO ENVIRONMENTAL CORP.
ESP ESPEY MANUFACTURING & ELECTRONICS CORP.
BHB BAR HARBOR BANKSHARES
MFIN MEDALLION FINANCIAL CORP.
BSM BLACK STONE MINERALS LP
PLSE PULSE BIOSCIENCES
MLP MAUI LAND & PINEAPPLE CO. INC.
CELC CELCUITY
BRT BRT APARTMENTS
CCEL CRYO-CELL INTERNATIONAL
AEYE AUDIOEYE INC
DLHC DALEIGH HOLDINGS CORP
OPCH OPTION CARE HEALTH INC
SMMT SUMMIT THERAPEUTICS INC
CTO CONSOLIDATED-TOMOKA LAND CO
PFBX PEOPLES FINANCIAL CORP. (MISSISSIPPI)
NAUT NAUTILUS BIOTECHNOLOGY INC
ENOV ENOVIS CORPORATION
PFHC PROFRAC HLDG CORP
MLYS MINERALYS THERAPEUTICS INC
PROP PRAIRIE OPERATING CO.
DMA DESTRA MULTI ALTERNATIVE FUND
CAMP CAMP4 THERAPEUTICS CORPORATION
SFD SMITHFIELD FOODS INC.
AFCG AFC GAMMA
HYMC INC.
NIQ HYCROFT MINING HOLDING CORPORATION
NIQ GLOBAL INTELLIGENCE PLC
Black Stone Minerals Lp: 1 director
A director at Black Stone Minerals Lp bought 25,370 shares at 12.081USD and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
- Jonathan Moreland
Perrigo Co: 1 director
A director at Perrigo Co maiden bought 1,255 shares at 22.410USD and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
Maui Land & Pineapple Company, Inc. Announces Strategic Evaluation of ...
Maui Land & Pineapple Company, Inc. Announces Strategic Evaluation of Water Source and Transmission Assets KAPALUA, Hawai‘i , Sept. 10, 2025 (GLOBE NEWSWIRE) -- Maui Land & Pineapple Company, Inc. (NYSE: MLP), today announced that a comprehensive strategic review has been underway and a subcommittee of the Company’s board of directors was created to identify options for the potential sale or lease of the Company’s water source and infrastructure assets. This review and marketing of certain assets for sale began in early 2025. MLP owns critical water-related assets on Maui, including sour...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.